CORAL GABLES, Fla., March 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is pleased to announce today the appointment of Bernardino Mosquera, M.D. as Vice President of Clinical Operations. Dr. Mosquera will be responsible for the operational oversight of Catalyst's clinical trials and the management of collaborations with clinical service providers such as clinical research organizations (CROs) and central laboratories.
"With our ongoing Phase III trial of FirdapseTM for the treatment of LEMS, this is an excellent time to welcome someone of Dr. Mosquera's caliber to our management team," said Steven Miller, Ph.D., Chief Operating Officer of Catalyst. "Dr. Mosquera's past experience will be an invaluable addition to our clinical programs, and we look forward to working with him."
For the past three years, Dr. Mosquera has been managing his own clinical research consulting company. As an independent consultant, he was involved in trials for Alzheimer's, Parkinson's, and stroke medications for a multinational pharmaceutical company and several biotech companies. Prior to his independent experience, he spent five years, first at Amgen, then as a dedicated contractor for Amgen, on a number of phase III trials in the oncology area. Prior to joining Amgen, he was with Kos Pharmaceuticals up until its acquisition by Abbott where he was involved in all aspects of clinical trial management for two Phase III trials for a hyperlipidemia treatment. This experience included CRO selection, site selection, vendor management, creating all study documents, IRB submissions, trial management, and CRA management.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether any of the Company's product candidates will ever be approved for commercialization and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CONTACT: For Further Information Contact: Patrick J. McEnany Catalyst Pharmaceutical Partners Chief Executive Officer (305) 529-2522 firstname.lastname@example.org Melody Carey Rx Communications Group Co-President (917) 322-2571 email@example.comSource:Catalyst Pharmaceutical Partners, Inc.